Advanced in Primary Lymphoma of the Brain

Dr. Iris Isufi

Hematology Oncology | Hematology | Oncology
Yale University
20 York St, 
New Haven, CT 
Offers Telehealth
18 Years of Experience
Advanced in Primary Lymphoma of the Brain
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Iris Isufi is a Hematologist Oncology specialist and a Hematologist in New Haven, Connecticut. Dr. Isufi has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma (MCL), and Bone Marrow Transplant.

Her clinical research consists of co-authoring 30 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Bridgeport Hospital
Lawrence & Memorial Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510
Other Locations
YALE UNIVERSITY
800 Howard Ave, New Haven, CT 06519

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Zelenoleucel
Study Phase: Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2025
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drugs: Cirmtuzumab, Ibrutinib
Study Phase: Phase 1/Phase 2
A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)
A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Nivolumab
Study Phase: Phase 2
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
View 7 Less Clinical Trials

29 Total Publications

A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.
Journal: Blood advances
Published: May 13, 2025
Similar Doctors
Distinguished in Primary Lymphoma of the Brain
Dr. Philip C. Caron
Oncology | Hematology
Distinguished in Primary Lymphoma of the Brain
Dr. Philip C. Caron
Oncology | Hematology

Msk Harrison

500 Westchester Ave, 
West Harrison, NY 
 (45.7 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Philip Caron is an Oncologist and a Hematologist in West Harrison, New York. Dr. Caron is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).

Advanced in Primary Lymphoma of the Brain
Dr. Jonathan E. Kolitz
Hematology Oncology | Hematology | Oncology
Advanced in Primary Lymphoma of the Brain
Dr. Jonathan E. Kolitz
Hematology Oncology | Hematology | Oncology

North Shore Health System Medical Faculty Group Practice Inc

27005 76th Ave, 
New Hyde Park, NY 
 (55.4 miles away)
718-470-4449
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Kolitz is a Hematologist Oncology specialist and a Hematologist in New Hyde Park, New York. Dr. Kolitz is rated as an Elite provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Leukemia, Chronic B-Cell Leukemia (CBCL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Distinguished in Primary Lymphoma of the Brain
Dr. Raphael E. Steiner
Oncology
Distinguished in Primary Lymphoma of the Brain
Dr. Raphael E. Steiner
Oncology

Msk Nassau

1101 Hempstead Tpke, 
Uniondale, NY 
 (53.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Raphael Steiner is an Oncologist in Uniondale, New York. Dr. Steiner is rated as an Elite provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration. Dr. Steiner is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Isufi's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 19 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile